-- UBS証券は金曜日、ライフタイム（LTH）は第1四半期に堅調な既存店売上高成長を達成し、売上高とEBITDAは予想を若干上回ると予想されると発表した。投資家は、軟調なマクロ経済環境下におけるセンター当たりの会員数増加指標や消費動向への懸念に注目している。 火曜日に発表される同社の第1四半期決算を前に、UBS証券は、第1四半期のEBITDA予想である2億1500万ドルに上方修正の余地があるとし、既存店売上高成長率は約7～7.5%になると予想していると述べた。 UBS証券によると、投資家の間で議論の中心となっているのは、消費支出の低迷が続く中で、同社が会員当たりの売上高とクラブ全体の収益性を維持できるかどうかだという。 UBS証券はまた、ライフタイムはスポンサーからの自社株買いを継続することで、過剰在庫の削減を図り、レバレッジ比率を目標の2倍未満に抑えることができると指摘した。 UBS証券はライフタイム株を「買い」とし、目標株価を43ドルとしている。
Price: $26.68, Change: $-0.13, Percent Change: -0.50%
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our 12-month price target by $45 to $235, reflecting a 25.6x multiple of our 2026 EPS estimate (down to $9.17 from $10.15; we cut our 2027 EPS estimate to $9.97 from $10.68), a discount to BIO's three-year historical forward average of 29.5x. Rather than a dramatic cut to National Institutes of Health (NIH) funding, Congress approved a modest increase for 2026 funding, helping reduce research budget concerns that loomed during 2025. However, BIO and peers anticipate that research spending growth from academic and early-stage biotech could remain muted over the near term as academic institutions adjust. The outlook for 2026 anticipates ongoing pressure, with BIO cutting sales and margin expectations during the Q1 earnings report, citing headwinds arising from the U.S.-Iran conflict in the Middle East such as weaker diagnostics sales and higher freight and fuel costs.
Pablo G. Mercado, Director, on April 30, 2026, sold 500 shares in Comfort Systems USA (FIX) for $889,890. Following the Form 4 filing with the SEC, Mercado has control over a total of 3,000 common shares of the company, with 3,000 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1035983/000153524626000004/xslF345X05/form4-05012026_040501.xml
Keith Harvey, Director, President & CEO, on April 29, 2026, sold 3,031 shares in Kaiser Aluminum (KALU) for $524,757. Following the Form 4 filing with the SEC, Harvey has control over a total of 94,308 common shares of the company, with 94,308 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/811596/000119312526201545/xslF345X05/ownership.xml